The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer

摘要: Objectives : The data on expression and clinical impact of cancer stem cell markers SOX2, NANOG OCT4 in lung is still lacking. aim our study was to compare SOX2 , mRNA levels whole blood between advanced small-cell (SCLC) patients healthy controls, correlate with progression-free survival (PFS) after first-line chemotherapy overall (OS) SCLC patients. Methods 50 treated standard followed at University Clinic Golnik, Slovenia, 2009 2013 were prospectively included. determined using TaqMan qPCR collected prior chemotherapy. Whole 34 matched individuals no cancerous disease also tested. Results significantly higher compared controls ( p = 0.006). Significant correlation the number distant metastatic sites established 0.027). In analysis, high had shorter OS 0.017) PFS 0.046). multivariate Cox an independent value for 0.002), but not confirmed. No significant differences observed or when comparing neither analysing outcomes Conclusion might be a promising non-invasive marker molecular screening important prognostic chemotherapy-treated patients, altogether indicating role CSC regulators spread. Further evaluation as possible screening/prognostic therapeutic target warranted.